Advanced salivary gland carcinoma expressing androgen receptor and HER2: targeted therapies first?
- 1 July 2020
- journal article
- letter
- Published by Elsevier BV in Annals of Oncology
- Vol. 31 (7), 958-959
- https://doi.org/10.1016/j.annonc.2020.03.302
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket studyAnnals of Oncology, 2019
- Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profilingCancer Medicine, 2019
- First Line Androgen Deprivation Therapy vs. Chemotherapy for Patients With Androgen Receptor Positive Recurrent or Metastatic Salivary Gland Carcinoma—A Retrospective StudyFrontiers in Oncology, 2019
- Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Salivary Duct CarcinomaJournal of Clinical Oncology, 2019
- Androgen Receptor Signaling in Salivary Gland CancerCancers, 2017